Danaher Corporation (NYSE:DHR) Shares Sold by M&T Bank Corp

M&T Bank Corp lowered its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 7.4% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 459,054 shares of the conglomerate's stock after selling 36,621 shares during the period. M&T Bank Corp owned 0.06% of Danaher worth $94,106,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the company. FAS Wealth Partners Inc. increased its holdings in Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares during the period. Horizon Financial Services LLC grew its stake in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after buying an additional 8,160 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the last quarter. Terra Alpha Investments LLC acquired a new position in Danaher during the 4th quarter valued at about $3,068,000. Finally, Rathbones Group PLC lifted its position in shares of Danaher by 2.5% during the 4th quarter. Rathbones Group PLC now owns 319,502 shares of the conglomerate's stock worth $73,342,000 after buying an additional 7,695 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DHR shares. Evercore ISI lowered their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday. Wells Fargo & Company lowered their price target on Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Argus reduced their price objective on Danaher from $260.00 to $240.00 in a research note on Wednesday, April 23rd. Barclays reaffirmed an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Finally, Robert W. Baird dropped their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $248.00.

Danaher Trading Up 0.5%

NYSE:DHR traded up $1.07 on Tuesday, hitting $200.70. The stock had a trading volume of 4,225,555 shares, compared to its average volume of 3,498,168. The company has a fifty day moving average price of $195.71 and a two-hundred day moving average price of $206.90. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70. The stock has a market cap of $143.63 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.85 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is presently 24.85%.

Insider Activity

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the transaction, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.